Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Appraisal of the references supporting the STOPP/START.version 3 criteria.

European geriatric medicine·2025
Same author

Improving usability of the STOPP/START version 3 criteria: development of a practice tool for clinicians, students and researchers.

European geriatric medicine·2025
Same author

Impact of deep learning image reconstruction on volumetric accuracy and image quality of pulmonary nodules with different morphologies in low-dose CT.

Cancer imaging : the official publication of the International Cancer Imaging Society·2024
Same author

Antipsychotic prescribing and drug-related readmissions in multimorbid older inpatients: a post-hoc analysis of the OPERAM population.

International journal of clinical pharmacy·2024
Same author

Assisting walking balance using a bio-inspired exoskeleton controller.

Journal of neuroengineering and rehabilitation·2023
Same author

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.

Gynecologic oncology·2023
Same journal

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026
Same journal

Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

Chemotherapy·2026
Same journal

Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

Chemotherapy·2026
Same journal

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

Chemotherapy·2026
Same journal

Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

Chemotherapy·2026
Same journal

Expression of Concern.

Chemotherapy·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potential interactions with anticancer agents: a cross-sectional study.

A Mouzon1, J Kerger, L D'Hondt

  • 1Department of Pharmacy, CHU Mont-Godinne Dinant, Université catholique de Louvain, Yvoir, Belgium.

Chemotherapy
|July 25, 2013
PubMed
Summary
This summary is machine-generated.

Cancer patients frequently experience clinically significant drug interactions (DIs) with anticancer agents, often leading to increased toxicity. Pharmacist collaboration and vigilant monitoring are crucial for managing these potential DIs.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: May 9, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

  • Oncology
  • Clinical Pharmacy
  • Pharmacology

Background:

  • Cancer patients face a high risk of drug interactions (DIs).
  • The prevalence and clinical significance of DIs involving anticancer agents remain under-investigated.
  • This study addresses the limited attention given to DIs in cancer care.

Purpose of the Study:

  • To evaluate the frequency of drug interactions involving anticancer agents.
  • To identify common anticancer drugs and co-medications implicated in DIs.
  • To assess the clinical significance and consequences of these drug interactions.

Main Methods:

  • A prospective study conducted in a Belgian teaching hospital.
  • Inclusion of 122 patients with solid malignancies.
  • Comprehensive drug history obtained by a clinical pharmacist and DI identification using three compendia.

Main Results:

  • Forty-one clinically significant potential DIs were identified in 25% of patients.
  • Cisplatin and methotrexate were frequently involved anticancer agents.
  • Increased toxicity of anticancer agents or co-medications was the primary adverse consequence, with <10% of DIs detected by all compendia.

Conclusions:

  • Preventive strategies are essential to mitigate drug toxicity and efficacy issues.
  • Routine surveillance of clinical and biological parameters is recommended.
  • Enhanced collaboration between prescribing physicians and clinical pharmacists can improve patient safety.